ライフサイエンスコーパス: efficacy against

1 loaded crosslinked MLNPs showed the highest efficacy against 3D spheroids of TNBC, in addition the M

2 The primary endpoint was vaccine efficacy against 6-month persistent infection or cervica

3 The primary endpoint was vaccine efficacy against 6-month persistent infection or cervica

4 ing-to-protocol cohort for efficacy, vaccine efficacy against 6-month persistent infection or CIN1+ a

5 We also noted significant cross-protective efficacy against 6-month persistent infection with HPV 3

6 o noted significant cross-protective vaccine efficacy against 6-month persistent infection with HPV 3

7 with the best compound (6p) retaining better efficacy against a broad panel of known INSTI resistant

8 ic insights into why a leading INSTI retains efficacy against a broad spectrum of drug-resistant vari

9 cin and CBP-vancomycin, and exhibits in vivo efficacy against a challenging multidrug-resistant and v

10 variety of cancer targets with unprecedented efficacy against a multitude of tumor types.

11 the bioactive form of CPT and show in vitro efficacy against a number of cancer cell lines.

12 Here we demonstrate its efficacy against a pandemic H1N1 challenge virus in the

13 eir inherent immunogenicity and demonstrated efficacy against a poorly immunogenic tumour, make CPMV

14 ved CAR T cells have demonstrated remarkable efficacy against a range of B-cell malignancies(1-3), an

15 ding pocket of WDR5 (the 'WIN' site) showing efficacy against a range of cancer cell lines in vitro.

16 l of aspergillosis, F901318 displays in vivo efficacy against a strain of A. fumigatus sensitive to t

17 QACs) had significant chain-length dependent efficacy against A. castellanii trophozoites, the latter

18 only licensed TB vaccine, provides variable efficacy against adult pulmonary TB, but why this protec

19 2-p53-binding interphase, and have low or no efficacy against advanced breast cancer with mutant or d

20 This is the first demonstration of vaccine efficacy against aerosol challenge with virulent type A

21 ate vaccine strains showed strong protective efficacy against AHSV infection in an IFNAR(-/-) mouse m

22 d we extend those studies to explore far-UVC efficacy against airborne human coronaviruses alpha HCoV

23 ng ALK rearrangements, demonstrates striking efficacy against ALK-rearranged NB.

24 ALK inhibitors have shown systemic efficacy against ALK-rearranged NSCLC in many clinical t

25 ree arenaviruses and demonstrated protective efficacy against all three targets.

26 Vaccine efficacy against all varicella was 95.4% (95% CI 94.0-96

27 essed RUNX1 and exerted in vitro and in vivo efficacy against AML cells expressing mtRUNX1.

28 Ab binding affinity and potential functional efficacy against AMR bacteria.

29 ely to engender resistance, will likely have efficacy against antibiotic-resistant strains, and may h

30 ograms on T. trichiura, without compromising efficacy against Ascaris lumbricoides and hookworm.

31 The observed vaccine efficacy against asymptomatic dengue virus infections is

32 Vaccine efficacy against atypical squamous cells of undetermined

33 eting human CD19 (hCD19) have shown clinical efficacy against B cell malignancies(1,2).

34 on tyrosine kinase inhibitor with remarkable efficacy against B-cell cancers.

35 liminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, ph

36 T cell therapy has shown remarkable clinical efficacy against B-cell malignancies, yet marked vulnera

37 Ibrutinib is associated with dramatic efficacy against B-cell malignancies.

38 en tested in vivo, azlocillin has shown good efficacy against B. burgdorferi in mice model.

39 ded vaccine development to maximize antibody efficacy against blood-stage malaria.

40 b and 15i showed significant antileishmanial efficacy against both extracellular promastigote (IC(50)

41 nt of novel broad-spectrum antibiotics, with efficacy against both gram-positive and gram-negative ba

42 Fragments retained efficacy against both soluble and tethered ligands with

43 hat control systemic disease have diminished efficacy against brain lesions.

44 nant negative ATF5 cargo have recently shown efficacy against brain, breast, melanoma, and prostate c

45 rs (PARPi) have shown remarkable therapeutic efficacy against BRCA1/2-mutant cancers through a synthe

46 t fields in Morocco were evaluated for their efficacy against C. capitata.

47 of MODIFY I/II was to assess bezlotoxumab's efficacy against C. difficile strains associated with in

48 In the present study, BKIs were screened for efficacy against C. parvum infection in the neonatal mou

49 eries of newly designed BKIs were tested for efficacy against C. parvum using in vitro and in vivo (m

50 ent on fruit productivity, juice quality and efficacy against 'Ca.

51 specific IgE antibodies might offer improved efficacy against cancer by recruiting key immune effecto

52 zymatic activity have not shown the expected efficacy against cancer in clinical trials, suggesting a

53 sponses with both preventive and therapeutic efficacy against cancer.

54 , a novel antifungal polyketide with in vivo efficacy against Candida albicans, was discovered using

55 identified small molecules were examined for efficacy against 'Candidatus Liberibacter asiaticus' in

56 Overall, the DISCII vaccine had 97% efficacy against cCMV.

57 ng to cell surface B7 ligands, with stronger efficacy against CD28.

58 cate that VSV-gp160G exerts potent oncolytic efficacy against CD4(+) malignant cells and either alone

59 Both treatments showed similar efficacy against ceftazidime-nonsusceptible pathogens.

60 spectively) and similar to the regimen's own efficacy against ceftazidime-susceptible infections (82.

61 testing novel HIV prevention strategies for efficacy against cell-associated HIV transmission.

62 pe 1 (HIV-1) are evaluated preclinically for efficacy against cell-free viral challenges.

63 maximum neutralization capacity or in vitro efficacy against cell-to-cell infection of HIV-1 with T/

64 conjugate vaccines (PCVs) have demonstrated efficacy against childhood pneumococcal disease in sever

65 In the total vaccinated cohort, vaccine efficacy against CIN1+ irrespective of HPV was significa

66 100 is the first therapeutic vaccine to show efficacy against CIN2/3 associated with HPV-16 and HPV-1

67 We used this panel to predict antibody efficacy against circulating HCV strains, highlighting t

68 modium falciparum and has partial protective efficacy against clinical and severe malaria disease in

69 (RTS,S) in children has demonstrated modest efficacy against clinical and severe malaria.

70 oite antibody titres predict the duration of efficacy against clinical malaria across different age c

71 ed phase III trials in 2014 and demonstrated efficacy against clinical malaria of approximately 36% o

72 dies are widely successful, yet have limited efficacy against CNS metastases, owing to the low levels

73 Safety and efficacy against coinfections with soil-transmitted helm

74 Studies of pneumococcal vaccine efficacy against colonization have been proposed as a no

75 s have been generated, few have demonstrated efficacy against congenital ZIKV infection.

76 ASAQ exhibited high efficacy against CQ resistant P. vivax and is an adequat

77 ort and long CARs targeting TSLPR and tested efficacy against CRLF2-overexpressing B-ALL.

78 ompound, MMV665917, has in vitro and in vivo efficacy against Cryptosporidium parvum.

79 ocyte exposure, resulting in reduced in vivo efficacy against Cryptosporidium.

80 Further studies are needed to establish its efficacy against current standard treatments and to inve

81 rolongs mammary tissue persistence, improves efficacy against DCIS lesions in vivo, and requires 5-fo

82 149 cases in the placebo group), with 95.4% efficacy against dengue leading to hospitalization (95%

83 Cumulative efficacy against dengue over ~27 months since first dose

84 conserved region of the M protein has shown efficacy against disease that follows i.p. inoculation o

85 en extensively characterized and shows broad efficacy against divergent H1N1 strains in the mouse mod

86 Seasonal influenza vaccines lack efficacy against drifted or pandemic influenza strains.

87 sources that have shown in-vivo and in-vitro efficacy against drug-resistant bacteria.

88 Covering spills decreased disinfection efficacy against E. coli on heavy-duty tarp but does pre

89 ine caramel and riboflavin enhanced the UV-B efficacy against E. coli strains at lower UV-B doses, wh

90 LY3023414 demonstrates efficacy against EAC in a preclinical model, establishin

91 otable achievement, its long-term protective efficacy against each of the 4 dengue virus serotypes re

92 dy responses and further improved protective efficacy against Ebola virus infection.

93 ment relative to its precursor in protective efficacy against EBOV and SUDV in guinea pigs.

94 OV and so far the only vaccine with reported efficacy against EBOV infections in humans in phase III

95 or continued monitoring of rotavirus vaccine efficacy against emerging rotavirus genotypes.IMPORTANCE

96 ct of intestinal transporters on therapeutic efficacy against enteric diseases has not been establish

97 u (CLsuGG) not only increases the antibiotic efficacy against Escherichia coli but also reduces adver

98 he hydroalcoholic extract showed the highest efficacy against Escherichia coli.

99 llowing ACT, resulting in superior antitumor efficacy against established solid and hematologic cance

100 ynthesized and evaluated for antileishmanial efficacy against experimental visceral leishmaniasis (VL

101 the circumsporozoite protein had on vaccine efficacy against first episodes of clinical malaria with

102 vely removes bacteria from surfaces, but its efficacy against fungi has not been fully tested.

103 a bovine genetic backbone, the high vaccine efficacy against G8 strains might be partially explained

104 hemotherapy drug for GBM increased antitumor efficacy against glioblastoma in experimental animals.

105 A kinase inhibitor alisertib exhibits potent efficacy against glioblastoma neurosphere tumor stem-lik

106 We demonstrate that one such conjugate shows efficacy against glioma stem-like cells.

107 , which exhibited high solubility and potent efficacy against Gram-negative pathogens in animal infec

108 ies of these molecules, derived from in vivo efficacy against Gram-positive and Gram-negative pathoge

109 xhibited antimicrobial activity, with higher efficacy against Gram-positive strains than Gram-negativ

110 human H2 influenza viruses, but the in vivo efficacy against H2 viruses is unknown.

111 rated superior immunogenicity and protective efficacy against H7N9 infection in ferrets and hold pote

112 otential targets to improve chemotherapeutic efficacies against HCC.

113 yet highly enhanced photodynamic inhibition efficacy against Hela cells under a broad spectrum of li

114 Estimated vaccine efficacy against herpes zoster in patients with solid tu

115 ine was well tolerated and estimated vaccine efficacy against herpes zoster was 16.8% (95% CI -17.8 t

116 Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence

117 against tumor necrosis factor alpha, showed efficacy against hidradenitis suppurativa.

118 In summary, EPOCH had broad efficacy against highly aggressive HIV-NHLs, whereas vor

119 livery, warranting further investigation for efficacy against HIV infections.

120 cine approach shown to elicit any protective efficacy against HIV-1 acquisition is based on a poxviru

121 the only HIV-1 vaccine trial to demonstrate efficacy against HIV-1 acquisition.

122 The RV144 trial was the first to show efficacy against HIV-1 infection.

123 e being advanced into field trials to assess efficacy against HIV-1 infection.

124 vo yet retains immunogenicity and protection efficacy against homologous and heterologous influenza v

125 ace of the VSV glycoprotein, have shown 100% efficacy against homologous filovirus challenge in roden

126 on particle) for safety, immunogenicity, and efficacy against homologous ID challenge with O. tsutsug

127 replication stress and enhances therapeutic efficacy against homologous recombination (HR) DNA repai

128 Oxantel pamoate had low efficacy against hookworm and A. lumbricoides.

129 Vaccine efficacy against hospitalization for dengue was 80.3%.

130 dels incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical c

131 Cumulative vaccine efficacy against HPV 16/18-associated CIN2+ over the 11-

132 The bivalent HPV vaccine has high efficacy against HPV 16/18-associated precancer for more

133 Vaccine efficacy against HPV 16/18-related 6-month persistent in

134 Vaccine efficacy against HPV 16/18-related cytological abnormali

135 Vaccine efficacy against HPV-31/33/45 for two-dose women who rec

136 Assuming 95% efficacy against HPV16 and HPV18 infections, the direct

137 his study, we report that gD/AS04 has higher efficacy against HSV-1 compared to HSV-2 genital herpes

138 AC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acqu

139 nate BETi resistance, exhibiting preclinical efficacy against human post-MPN sAML cells.

140 pounds exhibited modest, though significant, efficacy against human tumor lines and patient-derived x

141 wer systemic toxicity and higher therapeutic efficacy against i.p. chemotherapy-resistant uterine ser

142 tory approaches that continue to demonstrate efficacy against immune associated diseases.

143 antigens may not necessarily improve vaccine efficacy against immunodeficiency virus infection.

144 At year 11, vaccine efficacy against incident HPV 16/18-associated CIN2+ was

145 Vaccine efficacy against incident HPV-16/18 infection for two-do

146 We assessed vaccine efficacy against incident HPV-16/18 infection in the mod

147 Vaccine efficacy against incident HPV-16/18 infections for three

148 Vaccine efficacy against incident HPV-31/33/45 infections for th

149 uman papillomavirus (HPV) vaccines have high efficacy against incident infection and disease caused b

150 or sofosbuvir and velpatasvir had decreased efficacy against infection with the DBN3a sofosbuvir esc

151 Secondly, in vivo, we have investigated its efficacy against infectious bronchitis using a broiler i

152 In year 1, total vaccine efficacy against influenza A(H1N1)pdm09 was 14.5% (-20.4

153 In year 2, total vaccine efficacy against influenza A(H3N2) was 64.5% (48.5-75.5)

154 Total vaccine efficacy against influenza B was 32.5% (11.3-48.6) in ye

155 he study was not powered to evaluate vaccine efficacy against influenza infection.

156 broad-spectrum antiviral drug Arbidol shows efficacy against influenza viruses by targeting the hema

157 ingle oral dose of tafenoquine leads to high efficacy against intra-hepatocyte hypnozoites after effi

158 ing cellular immune responses and protective efficacy against intracellular pathogens.

159 nuating diarrhea and in providing protective efficacy against intraperitoneal Shigella infection.

160 Luteolin was subsequently examined for efficacy against L. asiaticus in Huanglongbing-infected

161 ority of studies focused on effectiveness or efficacy against laboratory supported influenza with lim

162 e assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza in infan

163 ve led to new immunotherapeutics with proven efficacy against late-stage cancers.

164 y using fluorescence microscopy to assess NF efficacy against latent HIV in the microglia cells.

165 CRISPR-Cas9/gRNA exhibits therapeutic efficacy against latent human immunodeficiency virus (HI

166 e with vaccination showed greater protective efficacy against lethal challenge, as evidenced by no lo

167 th GP and sGP DNA vaccines in mice and their efficacy against lethal Ebola virus challenge.

168 targeting this site show potent therapeutic efficacy against lethal EBOV challenge in mice.

169 f chronic myeloid leukemia (CML) has limited efficacy against leukemia stem cells (LSC) responsible f

170 -PQ metabolites (OH-PQm) are responsible for efficacy against liver and sexual transmission stages of

171 ncer stem cells and help advance therapeutic efficacy against lung cancers.

172 However, we detected no efficacy against M tuberculosis infection or disease, al

173 ormin enhances immunogenicity and protective efficacy against M. tuberculosis challenge.

174 , the immune responses necessary for vaccine efficacy against M. tuberculosis have not been defined.

175 mma and TNF is not a requirement for vaccine efficacy against M. tuberculosis, despite these cytokine

176 vaccine candidate, but only confers partial efficacy against malaria in children.

177 Protective efficacy against malaria, compared with daily proguanil,

178 Upon testing in vivo in a murine model of efficacy against malaria, high levels of compound exposu

179 med death ligand-1 (PD-L1) have shown marked efficacy against many advanced cancers, including those

180 in hematological malignancies, but clinical efficacy against many common solid epithelial cancers re

181 Cancer immunotherapy shows limited efficacy against many solid tumors that originate from e

182 whose potent antibacterial activity, in vivo efficacy against MDR A. baumannii infections and promisi

183 producing a remarkably improved therapeutic efficacy against MDR tumors with minimal side effects.

184 and apoptosis inhibition, which improved CTL efficacy against microsatellite instable and microsatell

185 an anti-SLAMF7 antibody, elotuzumab, showing efficacy against MM.

186 V and 67.2% (62.3-71.5) for MMR + V; vaccine efficacy against moderate or severe varicella was 99.1%

187 me CAR to be tested for toxicity in mice and efficacy against mouse and human tumors.

188 ) T cells show markedly improved therapeutic efficacy against mouse models of melanoma and leukaemia.

189 tion, we identify TLM analogues with in vivo efficacy against MRSA and Klebsiella pneumoniae in anima

190 e findings demonstrate that NDV-3 protective efficacy against MRSA in SSSI involves a robust and comp

191 gents exhibit in vitro activity and clinical efficacy against MRSA.

192 eed relatively high colistin daily doses for efficacy against multidrug-resistant and extensively dru

193 ls that provided no direct evidence of their efficacy against multidrug-resistant bacteria such as En

194 J379 and BC035) by profiling their antiviral efficacy against multidrug-resistant influenza A viruses

195 hibitor targeting GSK3beta with demonstrated efficacy against multiple diseases.

196 need for therapeutics with broad protective efficacy against multiple filoviruses.

197 s with improved drug kinetics and multistage efficacy against multiple human parasites.

198 nd DNA hypermethylation, has shown treatment efficacy against multiple malignancies by suppressing ep

199 ins have been shown to possess antimicrobial efficacy against multiple species of bacteria including

200 highly selective ELQs with outstanding oral efficacy against murine malaria that is superior to esta

201 terium bovis challenge in animal models, for efficacy against Mycobacterium leprae challenge in a mur

202 ary outcomes were immunogenicity and vaccine efficacy against Mycobacterium tuberculosis infection an

203 in-16, with increased potency and showed its efficacy against Neisseria gonorrhoeae in a mouse vagina

204 Secondary analyses included vaccine efficacy against non-vaccine oncogenic HPV types.

205 ent for influenza A is their universality or efficacy against not only seasonal variances in the infl

206 an M1, response may further improve vaccine efficacy against ocular HSV-1 replication and latency.

207 e HPV-16/18 endpoint), we calculated vaccine efficacy against one-time detection of incident HPV infe

208 easing in incidence among males, and vaccine efficacy against oral HPV infections in men has not been

209 the ACM showed extremely high antimicrobial efficacy against oral streptococci.

210 pharmacokinetic properties and prophylactic efficacy against organophosphate poisoning, showing its

211 NS5A inhibitors had varying levels of efficacy against original and resistant viruses.

212 armacokinetic profile, and demonstrates good efficacy against osteoarthritis pain in rodents.

213 The efficacy against oxidative degradation in model and sulp

214 (AAs), fatty acids (FAs), vitamins and their efficacy against oxidative stress.

215 Immunotherapy has only limited efficacy against pancreatic ductal adenocarcinoma (PDAC)

216 OH-PQm exert modest antimalarial efficacy against parasite gametocytes; however, potency

217 and spectrum, as well as examples of in vivo efficacy against pathogens including Staphylococcus aure

218 series also showed a nanomolar to picomolar efficacy against patient-derived GBM stem-like cells, th

219 y degrading BTK, IKFZ1, and IKFZ3 as well as efficacy against patient-derived xenografts in vivo.

220 The vaccine's efficacy against PCR-confirmed influenza illness and the

221 The vaccine's efficacy against PCR-confirmed influenza illness was hig

222 the linezolid AUC0-24/MIC target for optimal efficacy against pediatric intracellular tuberculosis, a

223 innamaldehyde (2-10%) showed high antifungal efficacy against Penicillium sp. and Aspergillus niger b

224 tion demonstrated the greatest antimicrobial efficacies against planktonic or biofilm bacteria.

225 unds were selected for evaluation of in vivo efficacy against Plasmodium berghei infection in mice on

226 t pneumococcal disease in infants, but their efficacy against pneumococcal community-acquired pneumon

227 enotype, and significantly improve antitumor efficacy against poorly immunogenic TNBCs.

228 om highly transcribed C1A, and evaluated its efficacy against pretreated corn stover and switchgrass.

229 e that a candidate P. vivax vaccine with low efficacy against primary infection may substantially red

230 estimate VES, and we also estimated vaccine efficacy against progression to symptoms (VEP).

231 and release free PTX after cell entry, shows efficacy against PTX-resistant ovarian cancer cells.

232 iations of trial setting and design with BCG efficacy against pulmonary and miliary or meningeal tube

233 survivin with SA-4-1BBL/MPL yielded superior efficacy against pulmonary metastases.

234 Univariable meta-regression indicated efficacy against pulmonary tuberculosis varied according

235 in), is given intradermally and has variable efficacy against pulmonary tuberculosis, the major cause

236 led(2), and with insecticidal bednets losing efficacy against pyrethroid-resistant Anopheles vectors(

237 on" INSTIs are needed that will have greater efficacy against RAL- and EVG-resistant strains of IN.

238 tors to develop compounds that have improved efficacies against recombinant IN in biochemical assays.

239 Compound 16 potentiated imipenem efficacy against resistant clinical and laboratory bacte

240 in per dose) to compare the relative vaccine efficacy against reverse-transcriptase polymerase-chain-

241 ts that modifications to RMP may recover its efficacy against RIF(R) TB.

242 fully optimized regimen), and increasing the efficacy against RR TB from 76% to 94% lowered RR TB mor

243 Protective efficacy against RSV challenge was not reduced by sG but

244 the 1960s not only showed a complete lack of efficacy against RSV infection but also induced severe l

245 meet the prespecified success criterion for efficacy against RSV-associated, medically significant l

246 mproved vector immunogenicity and protective efficacy against RSV.

247 ivity and in vivo protective and therapeutic efficacy against RSV.

248 that mediate broad protection and show high efficacy against seasonal and pandemic viruses are urgen

249 arget enzymatic profiles exhibited excellent efficacy against selected Gram-positive and Gram-negativ

250 jugates were screened for their photodynamic efficacy against several cancer cell lines expressing di

251 activity against HUVEC cells and anticancer efficacy against several cancer cell lines.

252 mber of potent antivirals with submicromolar efficacy against several human clinical isolates of infl

253 ells and is in clinical trials to assess its efficacy against several types of cancer.

254 (MERS-CoV) replication in vitro, and showed efficacy against Severe Acute Respiratory Syndrome (SARS

255 etween populations may contribute to reduced efficacy against severe rotavirus disease.

256 years in those in the placebo group; vaccine efficacy against severe rotavirus gastroenteritis was 53

257 vitro and in vivo tools to study antibiotic efficacy against Shigella flexneri.

258 distribution to liver, and increased in vivo efficacy against single or multiple targets with a singl

259 portant determinants of CD8+ T cell-mediated efficacy against SIV.

260 logic malignancies, but it has shown limited efficacy against solid tumors.

261 for some leukemias but provided only limited efficacy against solid tumors.

262 pies that induce T-cell responses have shown efficacy against some solid malignancies in patients and

263 d lethal pneumonia, providing broad-spectrum efficacy against staphylococcal invasive disease.

264 nosin B, is a potent antibiotic with in vivo efficacy against Staphylococcus aureus and Streptococcus

265 al period, has previously been shown to have efficacy against Staphylococcus aureus in in vitro and i

266 Their in vitro and in vivo efficacy against strain 536 and a ventilator-associated

267 adducts of various lengths were examined for efficacy against strains of influenza A including those

268 Vaccine efficacy against susceptibility to infection (VES), rega

269 The primary outcome was vaccine efficacy against symptomatic, virologically confirmed de

270 r primary objective was to assess protective efficacy against symptomatic, virologically confirmed de

271 ografts, PR-104 showed significantly greater efficacy against T-lineage ALL (T-ALL) than B-cell-precu

272 zole or mebendazole, but both drugs show low efficacy against T. trichiura.

273 as ricin, have been used, aiming for higher efficacy against target cells.

274 isoniazid and its individual contribution to efficacy against TB strains with inhA or katG mutations

275 develop additional agents that have improved efficacies against the existent resistant mutants.

276 to prevent acquisition may have differential efficacy against the different modes of transmission.

277 rase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot

278 so known as ABT-333) and ribavirin has shown efficacy against the hepatitis C virus (HCV) in patients

279 Testing vaccine efficacy against the highly lethal Ebola virus (EBOV) in

280 of the handful of drugs with proven clinical efficacy against the important opportunistic human patho

281 VEGFR2 and RET, and their antiproliferative efficacy against the medullary thyroid cancer cell line

282 These data show protective efficacy against the most pathogenic Angola strain of MA

283 emonstration of therapeutic anti-Ebola virus efficacy against the new outbreak strain in nonhuman pri

284 ut with emerging viral resistance and little efficacy against the oncogenic herpesviruses, there is a

285 of life, and the primary analysis of vaccine efficacy against the primary end point was performed in

286 te that the ROS1-selective inhibitors retain efficacy against the recently reported CD74-ROS1(G2032R)

287 iments are frequently used to determine drug efficacy against the survival and proliferation of cance

288 mor targeting selectivity, while the overall efficacy against the targeted tumor was not substantiall

289 ffinity maturation, improving its protective efficacy against three Ebolaviruses: EBOV, SUDV, and BDB

290 lavirus neutralizing activity and protective efficacy against three virulent ebolaviruses.

291 les (uPtDs NPs) and tested their therapeutic efficacy against TNBC metastasis.

292 P and elicited protective (43%) and TB (82%) efficacies against transgenic P. berghei parasites expre

293 However, benzimidazoles have low efficacy against Trichuris trichiura, and there are conc

294 utic agents because of their selectivity and efficacy against tumors resistant to conventional therap

295 Pibrentasvir had the highest level of efficacy against variants; viruses with RAS at amino aci

296 a naturally occurring HDP, and tested their efficacy against VEEV.

297 Although the DNA vaccine provided comparable efficacy against vertical transmission of ZIKV, the mRNA

298 erapeutic antibodies with improved antiviral efficacy against viral respiratory pathogens.

299 tly circulating influenza strains, they lack efficacy against viruses expressing divergent globular h

300 Vaccine efficacy against viruses with a lysine residue at site 1